November 11, 2009 – GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, announced data which demonstrate that obese patients with uncontrolled type 2 diabetes using the EndoBarrier™ Gastrointestinal Liner achieved near normalization of glycemic control in just one week, as compared to a sham control group. In addition, patients treated with EndoBarrier achieved a mean reduction of 2.4% in HbA1c glucose levels versus 0.8% for the sham arm at 24 weeks. Patients treated with EndoBarrier also achieved reductions in other diabetic factors including fasting blood glucose and weight. The results of the pilot study were published today in the current advance online issue of Diabetes Technology & Therapeutics.“Studies show that every one percent decrease in HbA1c reduces health risks by 21 percent and as the rates of obesity and type 2 diabetes continue to reach epidemic proportions around the globe, patients are in urgent need of new therapeutic solutions that overcome the limitations associated with pharmaceutical regimens and invasive surgery,... GI Dynamics' Press Release -
